The Medtronic Symplicty Spyral renal denervation ablation catheter expands inside the renal arteries and ablates nerves in the vessel wall to treat hypertension. [Illustration courtesy of Medtronic]Medtronic

美敦力Symplicty Spyral肾去神经消融导管在肾动脉内扩张并消融血管壁中的神经以治疗高血压。[插图由美敦力提供]美敦力

(NYSE: MDT)

（纽约证券交易所：MDT）

+

+

praised new European Society of Cardiology (ESC) 2024 guidelines for renal denervation (RDN) procedures for hypertension.

赞扬了新的欧洲心脏病学会（ESC）2024年高血压肾脏去神经支配（RDN）程序指南。

The ESC upgraded renal denervation to a Class IIb recommendation for patients with uncontrolled and resistant hypertension. Officials presented the new guidelines at the ESC Congress on Aug. 30 in London.

ESC将肾脏去神经支配升级为IIb级推荐，用于不受控制和耐药性高血压患者。官员们于8月30日在伦敦ESC大会上提出了新的指导方针。

Medtronic said the new guidelines outline patient selection criteria includes all adult patients with uncontrolled and resistant hypertension. They place emphasis on patients with high cardiovascular risk who remain uncontrolled. These patients express a preference to undergo RDN in a tailored, shared decision-making process..

美敦力表示，新指南概述了患者选择标准，包括所有未控制和耐药性高血压的成年患者。他们将重点放在心血管风险高且仍不受控制的患者身上。这些患者表示倾向于在量身定制的共享决策过程中接受RDN。。

According to Medtronic, the new guidelines are the second set from Europe, following ESH guidelines and consensus statements from leading countries. The medtech giant says these guidelines underscore the role of its Symplicity Spyral RDN system.

美敦力表示，新指南是继ESH指南和主要国家的共识声明之后，欧洲的第二套指南。这家医疗科技巨头表示，这些指南强调了其Symplicity Spyral RDN系统的作用。

Medtronic received a landmark approval for the system in November 2023. Approval made Medtronic the second company with such approval, following Recor Medical’s nod earlier that month.

美敦力于2023年11月获得了该系统具有里程碑意义的批准。该批准使美敦力成为第二家获得此类批准的公司，该公司于当月早些时候获得了Recor Medical的批准。

Symplicity Spyral delivers radiofrequency energy to nerves near kidneys in a minimally invasive procedure. These nerves can become overactive and contribute to high blood pressure. Medtronic’s RDN system holds approval for commercial use in more than 75 countries.

。这些神经可能变得过度活跃并导致高血压。美敦力的RDN系统已在75多个国家获得商业使用批准。

“Uncontrolled hypertension has a devastating impact around the world, which makes us further emboldened to provide innovative solutions like the Symplicity blood pressure procedure to patients who could potentially benefit,” said Jason Weidman, SVP and president of the Coronary and Renal Denervation business at Medtronic.

美敦力冠状动脉和肾脏去神经支配业务高级副总裁兼总裁杰森·魏德曼（JasonWeidman）表示：“不受控制的高血压在全球范围内具有毁灭性影响，这使我们更有勇气为可能受益的患者提供创新的解决方案，如Symplicity血压程序。”。

“These updated guidelines are also important for physicians as they reinforce RDN as an additional hypertension care option for those patients who may not respond adequately to lifestyle changes and medication management.”.

“这些更新的指南对医生也很重要，因为他们加强RDN作为那些可能对生活方式改变和药物管理反应不足的患者的额外高血压护理选择。”。